<code id='3404466597'></code><style id='3404466597'></style>
    • <acronym id='3404466597'></acronym>
      <center id='3404466597'><center id='3404466597'><tfoot id='3404466597'></tfoot></center><abbr id='3404466597'><dir id='3404466597'><tfoot id='3404466597'></tfoot><noframes id='3404466597'>

    • <optgroup id='3404466597'><strike id='3404466597'><sup id='3404466597'></sup></strike><code id='3404466597'></code></optgroup>
        1. <b id='3404466597'><label id='3404466597'><select id='3404466597'><dt id='3404466597'><span id='3404466597'></span></dt></select></label></b><u id='3404466597'></u>
          <i id='3404466597'><strike id='3404466597'><tt id='3404466597'><pre id='3404466597'></pre></tt></strike></i>

          Home / comprehensive / entertainment

          entertainment


          entertainment

          author:leisure time    Page View:5744
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In